Literature DB >> 9808514

Selective antitumor activity of MKT-077, a delocalized lipophilic cation, on normal cells and cancer cells in vitro.

Y Chiba1, T Kubota, M Watanabe, Y Otani, T Teramoto, Y Matsumoto, K Koya, M Kitajima.   

Abstract

BACKGROUND AND OBJECTIVES: 1-Ethyl-2-¿[3-ethyl-5-(3-methylbenzothiazolin-2-yliden)]-4-+ ++oxothiazolidin-2-ylidenemethyl¿pyridium chloride (MKT-077, formerly known as FJ776), a delocalized lipophilic cation, is known to accumulate in the mitochondria, according to the negative potential inside the mitochondria, and exert its cytotoxicity.
METHODS: The single-cell suspensions of human cancer cell lines, human spleen cells, and fresh cancer specimens obtained from patients with gastric carcinoma were used for the 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl-2H tetrazolium bromide (MTT) assay.
RESULTS: The antitumor activity of MKT-077 was dose and concentration related, and 50% inhibitory concentrations (IC50) ranged from 1.7 to 14.3 microg/ml, with a mean +/- standard deviation (SD) of 8.4 +/- 4.6 microg/ml. The IC50 of fresh surgical spleen-cell specimens ranged from 0.34 microg/ml to >100 microg/ml in a 48 h incubation, with a mean +/- SD of 66.5 +/- 37.7 microg/ml. When the antitumor activity of MKT-077 was compared between gastric cancer cells and spleen cells obtained from the same patient, the concentration-dependent antitumor activity of this agent was obvious in the cancer cells, while no significant cytotoxicity was observed in the spleen cells. The fresh surgical specimens of gastric cancer showed higher sensitivity to MKT-077 than did spleen cells at a concentration of 30 microg/ml, with a statistically significant difference at P < 0.05.
CONCLUSIONS: The selective antitumor activity of MKT-077 was confirmed using fresh surgical specimens and warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9808514     DOI: 10.1002/(sici)1096-9098(199810)69:2<105::aid-jso11>3.0.co;2-0

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  10 in total

Review 1.  Targeting Hsp70 facilitated protein quality control for treatment of polyglutamine diseases.

Authors:  Amanda K Davis; William B Pratt; Andrew P Lieberman; Yoichi Osawa
Journal:  Cell Mol Life Sci       Date:  2019-09-24       Impact factor: 9.261

2.  Allosteric drugs: the interaction of antitumor compound MKT-077 with human Hsp70 chaperones.

Authors:  Aikaterini Rousaki; Yoshinari Miyata; Umesh K Jinwal; Chad A Dickey; Jason E Gestwicki; Erik R P Zuiderweg
Journal:  J Mol Biol       Date:  2011-06-25       Impact factor: 5.469

3.  Synthesis and initial evaluation of YM-08, a blood-brain barrier permeable derivative of the heat shock protein 70 (Hsp70) inhibitor MKT-077, which reduces tau levels.

Authors:  Yoshinari Miyata; Xiaokai Li; Hsiu-Fang Lee; Umesh K Jinwal; Sharan R Srinivasan; Sandlin P Seguin; Zapporah T Young; Jeffrey L Brodsky; Chad A Dickey; Duxin Sun; Jason E Gestwicki
Journal:  ACS Chem Neurosci       Date:  2013-03-20       Impact factor: 4.418

Review 4.  Chemical Tools to Investigate Mechanisms Associated with HSP90 and HSP70 in Disease.

Authors:  Liza Shrestha; Hardik J Patel; Gabriela Chiosis
Journal:  Cell Chem Biol       Date:  2016-01-21       Impact factor: 8.116

5.  Mitochondrial autophagosomes as a mechanism of drug resistance in breast carcinoma.

Authors:  Ayman N Abunimer; Heba Mohammed; Katherine L Cook; David R Soto-Pantoja; Maria Mercedes Campos; Mones S Abu-Asab
Journal:  Ultrastruct Pathol       Date:  2018-02-08       Impact factor: 1.094

Review 6.  Targeting Allosteric Control Mechanisms in Heat Shock Protein 70 (Hsp70).

Authors:  Xiaokai Li; Hao Shao; Isabelle R Taylor; Jason E Gestwicki
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

7.  Uptake rate of cationic mitochondrial inhibitor MKT-077 determines cellular oxygen consumption change in carcinoma cells.

Authors:  John L Chunta; Kerry S Vistisen; Zeinab Yazdi; Rod D Braun
Journal:  PLoS One       Date:  2012-05-17       Impact factor: 3.240

8.  SMR peptide antagonizes mortalin promoted release of extracellular vesicles and affects mortalin protection from complement-dependent cytotoxicity in breast cancer cells and leukemia cells.

Authors:  Ming-Bo Huang; Jennifer Y Wu; James Lillard; Vincent C Bond
Journal:  Oncotarget       Date:  2019-09-10

Review 9.  Abrogating the Interaction Between p53 and Mortalin (Grp75/HSPA9/mtHsp70) for Cancer Therapy: The Story so far.

Authors:  Ahmed Elwakeel
Journal:  Front Cell Dev Biol       Date:  2022-04-14

10.  High Cytotoxic Activity of Phosphonium Salts and Their Complementary Selectivity towards HeLa and K562 Cancer Cells: Identification of Tri-n-butyl-n-hexadecylphosphonium bromide as a Highly Potent Anti-HeLa Phosphonium Salt.

Authors:  Barbara Bachowska; Julia Kazmierczak-Baranska; Marcin Cieslak; Barbara Nawrot; Dorota Szczęsna; Joanna Skalik; Piotr Bałczewski
Journal:  ChemistryOpen       Date:  2012-02-17       Impact factor: 2.911

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.